Cardiovascular Devices Market Overview
The increasing incidence of heart diseases is a notable factor driving the growth of the global cardiovascular devices market. According to the Centers for Disease Control and Prevention (CDC), coronary heart disease is the most common type of heart diseases which is responsible for over 370,000 deaths annually, in the U.S. Cardiovascular diseases mainly include coronary artery diseases (CAD) such as angina and myocardial infarction (commonly known as a heart attack). Stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, and venous thrombosis are some other types of cardiovascular diseases.
On the basis of product, the cardiovascular devices market has been categorized into cardiovascular monitoring and diagnostic devices, coronary stents, pacemakers, defibrillators, interventional cardiac devices, heart valves, cardiac ablation catheters, ventricular assist devices, and other devices. These devices are majorly used in the treatment of coronary heart disease, stroke, cerebrovascular diseases, rheumatic heart disease, and sudden cardiac arrest.
Hospitals, ambulatory surgery centers, and diagnostic clinics are the primary end users in the cardiovascular devices market. Among these, hospitals hold the largest share in this market and are expected to maintain this trend during the forecast period. Increasing patient base and large presence of skilled professionals in the hospital settings have been supporting the growth of this end-user category. Other than above mentioned end users, cardiovascular devices are also used in prehospital settings, at-home, schools, and workplaces.
North America is expected to lead the global cardiovascular devices market in the coming years, mainly due to the increasing awareness about various heart diseases, and growing obese population in the region. In addition, high disposable income and favorable reimbursement policies are also supporting the growth of the market in the region. Europe is expected to hold the second largest position in the global market, with Germany, France, and the U.K. holding a substantial share in the European cardiovascular devices market.
However, during the forecast period, the market in Asia-Pacific (APAC) is expected to witness the fastest growth. This is characterized by the surging geriatric population, rising number of cardiovascular disease cases, and large number of local players in the region.
Cardiovascular Devices Market Dynamics
Rising propensity toward minimally invasive surgeries (MIS)
Due to the leftover scars and pain caused by traditional surgeries, cardiac surgeons and patients have shifted their preference toward minimally invasive procedures. Some of the major advantages of MIS are that these surgeries do not require large incisions; involve low hospitalization expenditure, due to shorter hospital stay; and lead to faster post-operative recovery compared to an open surgery. Minimally Invasive Cardiac Surgery/Coronary Artery Bypass Grafting (MICS CABG) or the McGinn technique, is a heart surgery performed through several small incisions instead of the traditional open-heart surgery that requires a median sternotomy approach. Owing to these advantages of MIS, the patients prefer to opt for these surgeries, over conventional procedures.
Other than this, increasing awareness about the various treatment options for cardiovascular diseases, rapid technological advancements, and changing lifestyles have also been boosting the growth of the cardiovascular devices market.
However, stringent regulatory policies which delays product launches; high cost of instruments and their maintenance; lack of skilled professionals; and unfavorable market conditions for the new players are the major factors that hinder the growth of the cardiovascular devices market.
Rising number of product launches and increasing merger and acquisitions are the key trends observed in the market
A number of companies have been receiving government approvals for the launch and commercialization of cardiovascular devices. Along with this, the major market players are also acquiring other firms to increase their market share. For instance, in August 2018, Boston Scientific Corporation (Boston) acquired Claret Medical Inc. This acquisition was aimed at expanding the commercial portfolio of Boston by including Sentinel Cerebral Embolic Protection System, a device developed by Claret Medical Inc., that protect patients against the risk of stroke in transcatheter aortic valve replacement (TAVR) procedures.
Cardiovascular Devices Market Competitive Landscape
Ongoing product approvals in the cardiovascular devices market are expected to strengthen the position of the market players. For instance, in July 2018, Medtronic plc received United States Food and Drug Administration (USFDA) approval for a less-invasive implant approach of its HeartWare HVAD system, a left ventricular assisted device (LVAD) for patients with advanced heart failure. It is the smallest commercially available LVAD and has been approved in the U.S. for implant via thoracotomy, a small lateral surgical incision between the patient's ribs on the left side of the chest.
Moreover, in June 2018, LivaNova plc received approval from the Japanese Ministry of Health, Labour and Welfare for, Perceval, a suture less aortic heart valve to treat aortic valve disease. This approval in Japan was to provide advanced surgical options for the treatment of aortic valve diseases. Other than Medtronic plc and LivaNova plc, the cardiovascular devices industry includes players, such as Getinge Group, Terumo Corporation, Becton Dickinson and Company, Stryker Corporation, Abbott Laboratories, General Electric Company, Boston Scientific Corporation, Edwards Lifesciences Corporation, and W.L. Gore & Associates.
The study provides historical as well the forecast market size data for various countries including the U.S., Canada, Germany, the U.K., France, Italy, Spain, Japan, China, India, Brazil, Mexico, Saudi Arabia, South Africa.